Company profile: eGenesis
1.1 - Company Overview
Company description
- Provider of gene editing and genome engineering solutions to create human-compatible porcine organs and cells for transplantation. Offers HuCo organs and cells via the EGEN Platform, which addresses cross-species molecular incompatibilities and viral risks, enabling xenotransplantation to help address the global organ shortage.
Products and services
- HuCo™ organs and cells: Custom-engineered genetically engineered porcine organs and cells, developed via the EGEN™ Platform, for human transplantation, addressing organ shortages with human-compatible features
- EGEN™ Platform: Platform-level gene editing technology used to create human-compatible organs and cells by addressing cross-species molecular incompatibilities and viral risks during genome engineering
- Xenotransplantation: Cross-species transplantation process moving organs, tissues, or cells from pigs to humans, aimed at addressing the global shortage of transplantable human organs.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to eGenesis
LogicBio Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy vectors for previously incurable genetic and infectious diseases, committed to delivering genetic medicine to pediatric patients with rare diseases. Utilizes proprietary technology based on a non-pathogenic adeno-associated viral vector, offering superior efficiency and safety compared to competitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LogicBio Therapeutics company profile →
Tango Therapeutics
HQ: United States
Website
- Description: Provider of next-generation cancer therapies leveraging synthetic lethality, including TNG908 and TNG462, PRMT5 inhibitors for MTAP-deleted cancers; TNG260, a CoREST inhibitor aimed at reversing immune evasion in STK11-mutant cancers; and TNG348, a USP1 inhibitor for BRCA1/2-mutant and other HRD+ cancers, all in Phase 1/2 trials. Also provides a CRISPR-based functional genomics platform to identify synthetic lethal targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tango Therapeutics company profile →
Forma Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery, development and commercialization of transformative medicines leveraging biology and chemistry to address genomically validated cancer drivers; haemophilia A prophylaxis with Mim8 and the FRONTIER clinical programme; diabetes care for children; low-cost insulin access; humanitarian health partnerships; and haemophilia care support via a dedicated foundation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forma Therapeutics company profile →
Biocartis
HQ: Switzerland
Website
- Description: Provider of a diagnostics technology platform for multiplexed detection of bio‑analytes, focused on integrated molecular and immunodiagnostics via a proprietary micro‑technology platform. Products include the Idylla fully automated sample‑to‑result real‑time PCR system for molecular diagnostics from various biological samples, and assays such as APIS ESR1, Idylla BRAF, GeneFusion (research use), ctEGFR, and NRAS‑BRAF‑EGFR S492R.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocartis company profile →
Delfi Diagnostics
HQ: United States
Website
- Description: Provider of high-precision, non-invasive blood tests for early cancer detection, including the FirstLook Lung test using DNA fragment patterns; leverages machine learning and fragmentomics to analyze cell-free DNA fragments; and runs the CASCADE-LUNG clinical study to validate blood-based lung cancer screening technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delfi Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for eGenesis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to eGenesis
2.2 - Growth funds investing in similar companies to eGenesis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for eGenesis
4.2 - Public trading comparable groups for eGenesis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →